TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03835520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic Agent
Description: Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium.
Study: NCT04255563

Intervention type: DEVICE
Intervention: DCB treatment
Description: DCB (Sequent® Please) treatment for CAD patients will be enrolled. Intravascular ultrasound (Boston Scientific®) guidance is recommended.
Study: NCT06689709

Intervention type: OTHER
Group type: OTHER
Intervention: Serum Alkaline Phosphatase Levels
Description: Venous blood was drawn from the patients
Study: NCT02251470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HBE Wii (EG)
Description: Wii-Fit Balance games (Soccer Heading, Ski Slalom, Table Tilt, Balance Bubble etc.)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HBE Control (CG)
Description: Simple balance exercises with own body weight (Single limb stance, stepping, side sways etc.)
Study: NCT04448912

Intervention type: PROCEDURE
Intervention: Damage control surgery
Description: Surgery for non-traumatic abdominal emergencies using the damage control approach

Intervention type: PROCEDURE
Intervention: Conventional surgery
Description: Conventional surgery for non-traumatic abdominal emergencies
Study: NCT03835520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molecular Target
Description: Targeted agents will be administered according to standard of care and reimbursement modalities in Belgium. Targeted agents will be administered according to manufacturer's instructions.
Study: NCT02354248

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Triple stimulation technique
Description: Evoked motor potentials obtained by magnetic transcranial stimulation are usually used, in standard practice, to evaluate the corticospinal tract. This procedure combines two techniques: the magnetic stimulation and the electroneuromyography. It is based on the double collision principle between the descending central stimulation (magnetic) and the ascending peripheric stimulation, hereby suppressing the issue of desynchronisation of evoked motor potentials. The Triple stimulation technique allows a better quantification of the proportion of motor units activated by the transcranial stimulation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Triple stimulation technique
Description: Evoked motor potentials obtained by magnetic transcranial stimulation are usually used, in standard practice, to evaluate the corticospinal tract. This procedure combines two techniques: the magnetic stimulation and the electroneuromyography. It is based on the double collision principle between the descending central stimulation (magnetic) and the ascending peripheric stimulation, hereby suppressing the issue of desynchronisation of evoked motor potentials. The Triple stimulation technique allows a better quantification of the proportion of motor units activated by the transcranial stimulation.
Study: NCT02612662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4076
Description: Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4076
Description: Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4076
Description: Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4076
Description: Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4076
Description: Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4076
Description: Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection
Study: NCT00550732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: Posaconazole oral suspension was administered as 400 mg twice daily (bis in die, BID) with food or 200 mg four times daily (quater in die, QID) without food for a minimum of 1 month.
Study: NCT04286867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol Moderation Mobile Application
Description: This group will receive a link and in-person instructions on how to use the alcohol moderation application described. Individuals in this group will define their drinking limits within the application. The application will provide time points to aid the individual in maintaining their predefined drinking limits throughout the course of the drinking occasion. This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol Moderation Drink Tracker
Description: This group will receive the NIAAA tracking card and in-person instructions on how to use the drink tracker card (described at https://www.rethinkingdrinking.niaaa.nih.gov/Thinking-about-a-change/Strategies-for-cutting-down/Tips-To-Try.aspx). Individuals in this group will define their drinking limits, and record their alcohol consumption on the drink tracking card. This group will also receive training on the strategies for alcohol moderation recommended by NIAAA.
Study: NCT04462419

Intervention type: RADIATION
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Positron Emission Tomography
Description: Undergo PET-MRI imaging

Intervention type: OTHER
Intervention: Fluciclovine F18
Description: Given IV
Study: NCT03303248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Educational Intervention
Description: A web-based educational tool, created for patients with congenital heart disease, will be given to patients using an ipad. This additional educational tool will be used with the standard of care visit with provider.
Study: NCT02427620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT06687109

Intervention type: PROCEDURE
Intervention: Total Knee Arthroplasty
Description: Total Knee Arthroplasty

Intervention type: PROCEDURE
Intervention: Total Hip Arthroplasty
Description: Total Hip Arthroplasty
Study: NCT02853084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL2351
Description: The dose will be adjusted based on disease activities
Study: NCT04847037

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Connected tools
Description: Use of connected tools in postoperative bariatric follow-up vs no use of connected tools.
Study: NCT04191135

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion
Study: NCT01639690

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous CD34+ cells transduced with TNS9.3.55
Description: Patients will receive Filgrastim followed by apheresis of peripheral blood stem cells. CD34+ cells will be purified and transduced ex vivo. Transduced cells will be frozen in several aliquots whenever possible while vector copy number determination and biosafety testing are performed. Patients will be treated in the outpatient and/or inpatient units, and receive intravenous busulfan (8mg/kg) as non-myeloablative conditioning. Patients will be administered 2-12 x 10\^6 transduced CD34+ cells per kg in 1 or several infusions. A back-up of 2 x 10\^6 untransduced CD34+ cells per kg will be preserved for every patient.
Study: NCT03637816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anamorelin Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01627197

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery of percutaneous catheter system
Description: Intraarterial (IA) catheterization was done in the Department of Invasive Technology. All medications were administered using percutaneous catheter system via a modified Seldinger technique. An angiographic catheter was inserted through the femoral artery into the internal iliac artery. The catheter tips were located superior to the origin of bilateral common artery.
Study: NCT04603287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B001
Description: Administration by intravenous infusion.
Study: NCT04101331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFM13
Description: weekly intravenous infusions of 200mg
Study: NCT03889015

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt
Description: Probiotics are found in different dairy products including yoghurt, that are known as carriers of probiotics. These products can be easily integrated in daily meals to reduce cariogenic streptococcus mutans bacteria in dental biofilm

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: xylitol chewing gum
Description: Xylitol is widely used as an added sweetener in sugar-free products. It has been found to prevent dental caries through reducing dental plaque and limiting salivary streptococcus mutans counts and their produced levels of lactic acid
Study: NCT03191734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AQUABEAM System
Description: Aquablation is a minimally invasive transurethral surgical procedure using the AQUABEAM system, a personalized image-guided waterject resection system that utilizes a high-pressure saline stream to resect and remove prostate tissue.
Study: NCT04481438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupunch Exercises
Description: The acupunch exercise program was developed based on Jing-Luo theory of tranditional Chinese Medicine. The experiment group will receive Acupunch exercise for 40 minute sessions, 3 times a week, for 24 weeks
Study: NCT04193176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Administered twice daily as an oral tablet of 45 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered twice daily as a placebo oral tablet matching gefapixant
Study: NCT01027754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Days 1-3: 0.5 mg once a day Days 4-7: 0.5 mg twice a day Days 8-84: 1 mg twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Days 1-3: 1 pill daily Days 4-7: 2 pills daily Days 8-84: 2 pills daily
Study: NCT02529488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL
Description: Multifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
Study: NCT00324857

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Decision Aid Video
Description: The research interventionist will show the participant the Dartmouth Knee OA Decision Aid video entitled Treatment Choices for Knee Osteoarthritis. The video gives a detailed explanation of 1) the damage to the knee joint caused by OA; 2) treatment options including lifestyle changes, medications, injections, complementary therapy, and surgery; 3) the risks, benefits, and known efficacy of each treatment option.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: The research intervention will conduct the fact-to-face MI session with the participant. The MI session will do the following things: 1) Assessing Readiness, Importance, and Confidence; 2) Eliciting Barriers, Concerns and Positive Motivational; 3) Summarizing Pros and Cons; 4) Assess Patient Values and Goals; 5) Provide a Menu of Options.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MI plus Decision aid
Description: Patient viewed the video and then underwent MI.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Attention control
Description: patients received a booklet.
Study: NCT02459600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: instulling cyclopentolate drops in the eye
Description: measuring refraction with and wirthout cyclopentolate drops under general anesthesia
Study: NCT04254679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid analgesics
Description: Current standard of care in the participating centers Prescription of around-the-clock non-opioid analgesics (acetaminophen and/or NSAIDs/COX-2) and a supply of opioids to be used as a rescue in case of breakthrough pain.~The specific round-the-clock analgesia and rescue opioid regimens will be determined by the patient's primary surgeon considering the surgical procedure, comorbidities and patient's preference.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-opioid analgesics
Description: Prescription of around-the-clock non-opioid analgesics (acetaminophen alone or combined with NSAIDs/COX-2).~The specific non-opioid analgesia regimens will be determined by the patient's primary surgeon considering the surgical procedure, comorbidities and patient's preference.
Study: NCT02688621

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet Only
Description: 18 month behavioral weight loss intervention delivered online

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet + Incentives
Description: 18 month behavioral weight loss intervention delivered online with the possibility of earning incentives for losing weight and performing weight loss behaviors including monitoring food intake, exercising, and daily weighing
Study: NCT00716664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A treatment series of gentle joint and muscle movements
Description: Undertaken by a physiotherapist, weekly, for six weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group measurements
Description: The control group are measured using the same outcome measures at the same time intervals, but receive no active intervention
Study: NCT02571543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Beginning with 400mg Ibuprofen, 5 times. Depending on the outcome of stage 1 the treatment dose will increase to 800mg, 5 times.
Study: NCT02427620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study: NCT01363947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNIB0600A
Description: Several dose levels will be evaluated for DNIB0600A administered via IV infusion on Day 1 of each 21-day cycle until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNIB0600A
Description: Several dose levels will be evaluated for DNIB0600A administered via IV infusion on Day 1 of each 21-day cycle until disease progression.
Study: NCT02427620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT03516981

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W
Study: NCT03612414

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aqualief
Description: Three tablets/day
Study: NCT03516981

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W
Study: NCT03612414

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three tablets/day
Study: NCT04421664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days
Study: NCT01433653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Complicated Grief
Description: Manualized CBT with 25 sessions, once a week. Key elements are exposition and cognitive restructuring.
Study: NCT04421664

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days
Study: NCT02202265

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive oil
Description: 30ml a day of olive oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nuts
Description: 30g a day of nuts

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control diet
Description: Diet based on standard guidelines
Study: NCT01723839

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide
Description: 19 subjects are treated in stage-1 with FCR plus 5mg lenalidomide increasing to 10mg and 15mg in subsequent cycles depending on toxicity.
Study: NCT04241432

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vibrating platform
Description: Use of two different types of vibrating platform

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vibrating platform
Description: Use of two different types of vibrating platform
Study: NCT02466997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: tacrolimus 0.1% ointment applied twice a day for the experimental group during 24 weeks placebo ointment applied twice a day for the control group during 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00600704

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluid Restriction Policy
Description: Infusion of Hes 130/0.4 up to 500 ml until the beginning of Cardiopulmonary bypass

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free fluid infusion
Description: Free fluid infusion unless Hb\< 6g/dl(allogenic blood use), until the beginning of Cardiopulmonary bypass
Study: NCT01509404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Description: Valcyte per package insert guidelines for 200 days post transplant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CMV hyperimmune globulin
Description: 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Description: valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant